RA Capital
Venture capitalActively deployingBoston · Seed–Late Stage · 29 people tracked
Also known as RA CAPITAL MANAGEMENT, LP · RA Capital Nexus · RA Capital Nexus International · RA Capital Planetary Health · RA Capital Planetary Health International
Investment thesis
RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.
Source: firm website, verified Aug 11, 2026.
Team · 29 people
from public directories
What they invest in
from 112 of 272 portfolio companiesBiotech ×97Medical Devices ×41Healthtech ×38Deep Tech ×14Digital Health ×13AI & Machine Learning ×11SaaS ×3Advanced Manufacturing ×2
HQs:United States×103United Kingdom×2Canada×1China×1Denmark×1Netherlands×1
Investments · 272 tracked
founders shown can be your intro pathBy year:2026 · 72025 · 92024 · 62023 · 32022 · 32021 · 92020 · 52019 · 32018 · 12017 · 22016 · 22015 · 657 dated
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon
Riley Ennis(Co-Founder and Chief Product Officer)Stuart Lawson(Director)Charles Roberts(Director)Gabriel Otte(Director)
Clinical stage oncology company developing cancer drugs paired with companion diagnostics; went public on NASDAQ (ACRV) in 2022.
Watertown, US
Board seatDerek DiRocco· per SEC Form D
BiotechSan Diego, US
Jonathan Leff(Director)Richard Lowenthal(Executive Officer, Director)Pratik Shah(Director)
Board seatPeter Kolchinsky· per SEC Form D
Palo Alto, US
Janice Drew(Executive Officer)David Cohen(Director)Robert Hopfner(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)Francois Beaubien(Director)
Board seatDerek DiRocco· per SEC Form D
Clinical-stage biopharmaceutical company committed to developing best-in-class novel therapy for hypertension treatment.
BiotechRadnor, US
Adam Levy(Executive Officer)Srinivas Akkaraju(Director)Alexander Asam(Director)
BoardBrian Taylor Slingsby(Director)Olivier Litzka(Director)
Board seatDerek DiRocco· per SEC Form D · $118M raise · filed Jun 2022
BiotechCambridge, US
Patrick Vink(Director)Milind Deshpande(Director)Jean-Francois Formela(Director)Casper Breum(Director)Ankit Mahadevia(Executive Officer, Director)Stephen Garbacz(Executive Officer)
Board seatReza Halse· per SEC Form D
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.
BiotechHealthtechMedical DevicesWayne, US
Neal Walker(Executive Officer, Director)Joseph Monahan(Executive Officer)Hugh Davis(Executive Officer, Director)James Loerop(Executive Officer)Kevin Balthaser(Executive Officer)Kamil Ali-Jackson(Executive Officer)
HealthtechLaguna Hills, US
Andrew Wade(Executive Officer)Michael Zhao(Director)Olav Bergheim(Executive Officer, Director)James Cox(Director)
BiotechAustin, US
Charles N. York(Executive Officer)David G. Lowe(Executive Officer, Director)Henry Skinner(Director)George Georgiou(Director)Armen Shanafelt(Director)
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)Patrick Baeuerle(Co-founder & Advisor)Shulamit Ron-Bigger(Executive Officer)
BoardHelen S. Kim(Director)Oleg Nodelman(Director)Andrew Levin(Director)
Apogee Therapeutics develops novel antibody therapeutics targeting biological drivers of inflammatory and immune diseases, aiming to improve on the standard of care.
Biotech
BiotechWestlake Village, US
Alexander Asam(Director)Ricky Sun(Director)Jonathan Silverstein(Director)Todd Franklin Watanabe(Executive Officer, Director)
BoardPatrick Heron(Director)Daniel Estes(Director)
BiotechBoston, US
Bruno Lucidi(Director)Jean-Pierre Sommadossi, Ph.D.(Executive Officer, Director)Evgeny Zatsev(Director)Frank Yu(Director)Gerald Chan(Director)Bruce Polsky(Director)
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.
BiotechHealthtechLongevityRichmond, US
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Eric Morgen(Director)Dov Goldstein(Executive Officer)Jason Coloma(Director)Kristen Fortney(Executive Officer, Director)
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Benjamin Cravatt, Ph.D.(Director)Ho Sung Cho, Ph.D.(Director)Carolyn Ng, Ph.D.(Director)Jakob Loven, Ph.D.(Director)Zachary D. Hornby(Executive Officer, Director)Jonathan E. Lim, M.D.(Director)
C4 Therapeutics develops small molecule medicines called degraders that use targeted protein degradation (TPD) to eliminate disease-causing proteins via the body's ubiquitin proteasome system.
BiotechCambridge, US
Marc Cohen(Executive Officer, Director)Jason Fisherman(Executive Officer, Director)Miles Stuchin(Director)William M. Scalzulli(Director)Kenneth Anderson(Director)Malcolm S. Salter(Director)
Ceribell develops a point-of-care EEG system that uses AI to detect seizure activity, including status epilepticus, in patients.
AI & Machine LearningHealthtechMedical DevicesSunnyvale, US
Joseph Taylor(Director)Scott Blumberg(Executive Officer)Lucian Iancovici(Director)Raymond Woo(Executive Officer)Josef Parvizi(Director)David Stoffel(Executive Officer)
BiotechCambridge, US
Sara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)Robert Hopfner(Director)Mette Kirstine Agger(Director)James G. McArthur(Executive Officer, Director)
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)
Precision BioSciences is a clinical-stage biotechnology company developing genome-editing therapies based on its ARCUS platform.
BiotechDeep TechHealthtechDurham, US
JEFF SMITH(Executive Officer)DEREK JANTZ(Executive Officer, Director)MATTHEW KANE(Executive Officer, Director)TODD MELBY(Executive Officer)BEN AUSPITZ(Director)Jeff Smith(Co-founder)
Boston, US
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder & CEO)Jennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)
BoardVijay Pande(Director)
Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Matthew Henn(President and Chief Scientific Officer)
BiotechCharlestown, US
Lynne Sullivan(Director)Adam Koppel(Director)Stephen DiPalma(Executive Officer)Martin Freed(Director)Alexander (Bo) Cumbo(Executive Officer, Director)Paul Herizch(Executive Officer)
SpyGlass Pharma develops a sustained drug delivery system, the BIM-IOL System, that integrates long-acting glaucoma therapy into cataract surgery.
BiotechHealthtechMedical Devices
Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.
BiotechHealthtech
Xilio (Xilio Therapeutics) is a clinical-stage biotechnology company developing tumor-selective immunotherapies, including checkpoint inhibitors, T cell engagers and related molecules, for the treatment of cancer.
BiotechHealthtechWaltham, US
Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)Rachel Humphrey(Director)Daniel Lynch(Director)Michael Ross(Director)
Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.
BiotechHealthtechMedical DevicesAustin, US
Shanshan Xu(Founder & Chief Executive Officer)Helmut Jeggle(Co-Founder)Thang Ho(Chief Development Officer)Crystal MacKay(Chief Operating Officer)
Board seatDerek DiRocco· per SEC Form D
Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.
BiotechDeep TechMedical DevicesSeattle, US
Marc Lajoie(Co-founder & Chief Executive Officer)Scott Boyken(Co-founder & Chief Technology Officer)Stanley Riddell(Co-Founder and Scientific Advisor)Aaron Foster(Executive Officer)Charity Scripture(Executive Officer)Eric Soller(Executive Officer)
Board seatJake Simson· per SEC Form D
Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients.
BiotechHealthtechCambridge, US
Aaron Ring(Co-founder)Aashish Manglik(Co-founder)Jeff Landau(Chief Executive Officer)Roland Gendron(Chief Business Officer)Michelle Zhang(Chief Scientific Officer)
BoardVineeta Agarwala(Director)
Board seatDerek DiRocco· per SEC Form D
Abcuro is a clinical-stage biopharmaceutical company developing ulviprubart, a monoclonal antibody that selectively depletes highly cytotoxic T cells by targeting the KLRG1 receptor.
BiotechHealthtechNewton, US
John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Ryan Berry(Director)Donald McCarthy(Director)John Edwards(Director)Yajun Xu(Director)
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.
AI & Machine LearningBiotechDeep TechHealthtech
Jane Osbourn(Chief Executive Officer)
Avalanche Energy develops compact fusion technology to generate high-energy neutrons for materials testing, radioisotope production, and advanced nuclear battery systems serving defense, space, and commercial power applications.
Deep TechDefense TechEnergyRichland, US
Robin Langtry
Hyku Biosciences develops covalent medicines to improve patient outcomes by advancing the scientific boundaries of this therapeutic approach.
BiotechDeep TechMedical DevicesBurlington, US
KLEEM CHAUDHARY(Executive Officer, Director, Promoter)Kleem Chaudhary, PhD(President & CEO)Ku-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)
BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)LAURA TADVALKAR(Director)
Kinaset Therapeutics is a biopharmaceutical company developing respiratory drug therapies.
BiotechHealthtechMedfield, US
Tom King(Director of the Issuer)Roger Heerman(Chief Business/Operating Officer / Co-Founder)Frazer Morgan(Chief Development Officer / Co-Founder)Bram Vanparys(Director of the Issuer)Robert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)
Sydnexis is a privately held biopharmaceutical company developing SYD-101, a proprietary low-dose atropine formulation in Phase 3 clinical trials to slow the progression of pediatric progressive myopia.
BiotechDigital HealthDel Mar, US
Patrick Johnson(Executive Officer, Promoter)Mary Jaqueline Johnson(Executive Officer)Mary Jacqueline Johnson(Executive Officer)Kevin Johnson(Director)Greg Ostrow(Executive Officer, Director)Kenneth Widder(Executive Officer, Director)
Vivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types.
BiotechHealthtechMedical DevicesSan Mateo, US
Shuang Qiao(Executive Officer, Director)Sheng Ding(Executive Officer)
BoardEdward Hu(Director)Jun Wu(Director)Jake Simson(Director)Tim Shannon(Director)
Structure-based small-molecule drug design targeting protein aggregation diseases.
BiotechThousand Oaks, US
Gary Wilcox(Director)James Treanor(Also a former CEO)John Frank(Director)Madhavan Balachandran(Executive Officer, Director)
Board seatReza Halse· per SEC Form D · $6M raise · filed Dec 2020
Browse all 272 investments with full details →
▶72 more tracked companies
NapiGenNavaNavigator MedicinesNexCureNextopNiKang TherapeuticsNimbus TherapeuticsNivalisNorthLinks BioNucleixObsidian TherapeuticsOlemaOllinOptivoltOrchardPAhR TherapeuticsPandionPelotonPhathomPinnacle MedicinesPluton BioPMV PharmaPoint BiopharmaPoplar TherapeuticsPrevailProfound BioProtagonistRa PharmaceuticalsRadenceReframe SystemsRivus PharmaSatsumaSecretome TherapeuticsSerapha BioShockwaveSidera BioSierra OncologySilverback TherapeuticsSlate MedicinesSomatusSortera TechnologiesSparrow PharmaStar TherapeuticsStokeStylus MedicineSuperluminalSynapticureSynolo TherapeuticsSynthekineSynthorxT-KnifeTaris BiomedicalTassoTenayaTerremoto BiosciencesterrestrialThriveworksTorl BioTrace NeuroscienceTriana BioTscanTypewriter TherapeuticsTyraVentus TherapeuticsVerdiva BioVerve TherapeuticsViacyteVitriVaxVividionVoro MetalsWhiteSwellWindward Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 49
IPOs and acquisitions across the tracked portfolioFreenomeNASDAQ: FRNMAcrivon TherapeuticsNASDAQ: ACRVARS PharmaceuticalsNASDAQ: SPRYArtiva BiotherapeuticsNASDAQ: ARTVEvommuneNYSE: EVMNMineralys TherapeuticsNASDAQ: MLYSSepternaNASDAQ: SEPNSpero TherapeuticsNASDAQ: SPROWave Life SciencesNASDAQ: WVE(IPO) NASDAQ: NTRAAclaris TherapeuticsNASDAQ: ACRSAdagio MedicalNASDAQ: ADGMAeglea BiotherapeuticsNASDAQ: SYREAktis OncologyNASDAQ: AKTSAN2 TherapeuticsNASDAQ: ANTXApogee TherapeuticsNASDAQ: APGEArcutis BiotherapeuticsNASDAQ: ARQTArvinasNASDAQ: ARVNAtea PharmaceuticalsNASDAQ: AVIRBicara TherapeuticsNASDAQ: BCAXBioAge LabsNASDAQ: BIOABiohavenNYSE: BHVNBlack Diamond TherapeuticsNASDAQ: BDTXBolt BiotherapeuticsNASDAQ: BOLTBoundless BioNASDAQ: BOLDC4 TherapeuticsNASDAQ: CCCCCentury TherapeuticsNASDAQ: IPSCCeribellNASDAQ: CBLLCG OncologyNASDAQ: CGONClimbbioNASDAQ: CLYMConnect BiopharmaNASDAQ: CNTBDesign TherapeuticsNASDAQ: DSGNGH ResearchNASDAQ: GHRSImaraNASDAQ: ELVNnKartaNASDAQ: NKTXParabilis MedicinesNASDAQ: PBLSPepGenNASDAQ: PEPGPrecision BioSciencesNASDAQ: DTILPyxis OncologyNASDAQ: PYXSRxsightNASDAQ: RXSTScribe TherapeuticsNASDAQ: SCTXSeres TherapeuticsNASDAQ: MCRBSionna TherapeuticsNASDAQ: SIONSolid BiosciencesNASDAQ: SLDBSpyglass PharmaNASDAQ: SGPVaxcyteNASDAQ: PCVXVor BiopharmaNASDAQ: VORXilio TherapeuticsNASDAQ: XLOJnana Therapeuticsacq. by Otsuka
Portfolio news
latest coverage across their companiesModerna · forbes.com · Jul 19, 2026
Ascendis Pharma · dailypolitical.com · Jul 18, 2026
(IPO) · tickerreport.com · Jul 18, 2026
Gameto · smartcompany.com.au · Jul 17, 2026
terrestrial · technologies.org · Jul 15, 2026
Nava · endpoints.news · Jul 15, 2026
Koloma · mcj.vc · Jul 14, 2026
Azalea Therapeutics · newmarketpitch.com · Jul 13, 2026
Public market activity · per SEC filings
what is this? ⓘ2 insider ownership filings (Forms 3/4/5)
at Hemab Therapeutics Holdings, Inc. (COAG)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- What stage does RA Capital invest at?
- RA Capital invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What sectors does RA Capital focus on?
- RA Capital focuses on Biotech, Medical Devices.
- Where is RA Capital located?
- RA Capital is headquartered in Boston, US.
Media · Podcasts & interviews
featuring the teamThe Investor's Paradox with Peter Kolchinsky, RA Capital
Incubate Coalition · Peter Kolchinsky
Images
Co-investors · 70
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.
Bain Capital Life Sciences, founded in 2016, invests in biopharmaceutical, medical device, diagnostic, and life science tool companies globally, focusing on companies addressing unmet medical needs and driving medical innovation.
Andreessen Horowitz's Strategic Partnerships page describes collaborations that connect its portfolio companies with established institutions to help scale and deploy their technology.
Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
F-Prime Capital Partners is a venture capital firm whose team of scientists, engineers, physicians, operators, and investors supports companies in scaling and accelerating growth.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
Canaan is an early-stage venture capital firm backing founders with transformative ideas across technology and healthcare.
Samsara BioCapital is an investment firm backing the development of transformative therapeutics for patients, bringing together scientists, physicians, drug developers, and business leaders to support next-generation therapeutic breakthroughs.
▶58 more co-investors
ARCH Venture PartnersvenBio PartnersThird Rock VenturesAisling CapitalMRL Ventures FundAtlas VentureVersant VenturesSR One Capital ManagementSV Health InvestorsAndera PartnersGeneral CatalystArtis VenturesMPM CapitalRed Tree VentureNew Enterprise Associates (NEA)US Venture PartnersEQT Life SciencesForbionPfizer Venture InvestmentsHatteras Venture PartnersHumboldtPolaris PartnersPlayground GlobalThe Column GroupNovartis Venture FundYsios CapitalRoche Venture FundAnzu PartnersMedical Excellence CapitalHealthCapPsyMed VenturesOverwater Ventures LlcInsight PartnersUnknown VenturesKleiner PerkinsCoatue ManagementAtomicoSignalFireVenrockTwo Sigma Ventures23andMeBaruch Future VenturesJohnson & Johnson Innovation – JJDCMithril Capital ManagementXSeed CapitalPivotal bioVenture PartnersAccess IndustriesOmega FundsQiming Venture PartnersTencent HoldingsNew Leaf Venture PartnersCofounders CapitalVertex Ventures HCAbbVieDe Novo VenturesQiming Venture Partners USARTW Investments L.P.Negev Capital
Firms observed investing alongside RA Capital, from public investor directories. Shared companies are the overlap with RA Capital's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
Pappas Capital is a life sciences venture capital firm that invests in and helps build companies developing next-generation life science products and technologies.
Excel Venture Management is a venture capital firm that builds and invests in companies applying life science technologies to problems in healthcare and other areas.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.